Search results for: 'make fuels develop deceleration'

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

This Frost Radar™ investigates the growth and innovation activity of clinical decision support system (CDSS) providers in their pursuit to help end users take the next best medical care action. A CDSS provides professionals with access to organized clinical knowledge integrated with the patient’s medical profile to improve their health and overall ...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report ...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

The laboratory information management systems (LIMS) industry in the United States and Europe is forecast to grow from 2023 to 2027 at a CAGR of 8.8% and 6.3%, respectively, driven by the increasing need for laboratory automation, regulatory compliance, and cloud-based solutions. Prominent players in the US and EU LIMS industries, such as ThermoFis...

Non-alcoholic steatohepatitis (NASH) is a chronic liver condition whose prevalence across the globe continues to rise year on year. The liver disorder is considered very dangerous as its symptoms can be mistaken for other liver disorders and conditions. Moreover, the disease can quickly progress to result in liver failure for the patients. The incr...